So we’re agreed - some kind of capital raise will be needed (as outlined in LTR’’s own recent presentation) prior to end of 2023.
Thats not FUD. That’s fact @TrayonRanger
So Debt or Equity? There are advantages and disadvantages to both (this is by no means an exhaustive list)…
Broadly speaking:
1. Equity - no repayment obligation but you surrender a portion of the company (usually at a discount). Non participation can dilute current holders BUT - Places no additional financing obligation on the company which frees up working capital (no monthly interest repayments etc).
2. Debt - doesn’t require giving up a portion of the company but does require repayment, normally with a decent interest rate premium attached and can carry financial caveats and penalties if not met in a timely manner. Also debt financing can come with restrictions that limit what the company can do.
To me - given the global uncertain economic outlook and the tools that central banks have - raising interest rates are one of the only levers that many have of controlling inflation - IMO this rules Debt financing out for LTR and they will need to go down some sort of Equity financing route in the not too distant future.
DYOR IMO
- Forums
- ASX - By Stock
- LTR
- Ann: Appointment of Chief Financial Officer
Ann: Appointment of Chief Financial Officer, page-53
-
-
- There are more pages in this discussion • 51 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add LTR (ASX) to my watchlist
|
|||||
Last
96.8¢ |
Change
-0.003(0.26%) |
Mkt cap ! $2.352B |
Open | High | Low | Value | Volume |
97.0¢ | 97.5¢ | 96.0¢ | $2.992M | 3.095M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
17 | 128485 | 96.5¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
97.0¢ | 172214 | 17 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
20 | 140652 | 0.965 |
20 | 452107 | 0.960 |
17 | 694651 | 0.955 |
47 | 553457 | 0.950 |
11 | 212131 | 0.945 |
Price($) | Vol. | No. |
---|---|---|
0.970 | 173183 | 16 |
0.975 | 207869 | 22 |
0.980 | 66553 | 9 |
0.985 | 170073 | 5 |
0.990 | 119425 | 6 |
Last trade - 10.48am 16/07/2024 (20 minute delay) ? |
Featured News
LTR (ASX) Chart |
The Watchlist
RCE
RECCE PHARMACEUTICALS LTD
James Graham / Dr Alan Dunton, MD & CEO / Non-Executive Director
James Graham / Dr Alan Dunton
MD & CEO / Non-Executive Director
SPONSORED BY The Market Online